Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
AIM ImmunoTech ( (AIM) ) has shared an announcement.
On January 20, 2026, AIM ImmunoTech notified holders of its Class E common stock purchase warrants of changes triggered by a stock dividend issued on January 13, 2026, in which shareholders received one share of common stock for every 1,000 shares outstanding as of January 9, 2026, and one share for every outstanding option or warrant entitled to stock dividends. The stock dividend constituted a Share Combination Event that, under the warrant terms, required an adjustment: during the defined evaluation period the volume-weighted average price fell below the floor price, leading the company to reduce the Class E warrant exercise price to $1.439 per share and inversely increase the number of outstanding Class E warrants to 5,561,125, while confirming that this pricing floor prevents further similar adjustments under the same provision going forward.
The most recent analyst rating on (AIM) stock is a Sell with a $1.00 price target. To see the full list of analyst forecasts on AIM ImmunoTech stock, see the AIM Stock Forecast page.
Spark’s Take on AIM Stock
According to Spark, TipRanks’ AI Analyst, AIM is a Underperform.
The score is primarily weighed down by very weak financial performance (large losses, negative equity, and ongoing cash burn). Technicals also remain unfavorable with a broader downtrend and negative MACD, while valuation is constrained by negative earnings and no dividend support. A recent corporate update further underscored significant development and funding/regulatory risks.
To see Spark’s full report on AIM stock, click here.
More about AIM ImmunoTech
AIM ImmunoTech Inc. is a biopharmaceutical company focused on developing its experimental drug Ampligen for the treatment of multiple viral diseases, cancers and immune-deficiency disorders, with its activities centered on extensive testing and clinical trials whose outcomes remain uncertain and subject to significant regulatory and operational risks.
Average Trading Volume: 109,113
Technical Sentiment Signal: Strong Sell
Current Market Cap: $3.94M
Learn more about AIM stock on TipRanks’ Stock Analysis page.